The discovery of the roles of C-MYC and the Ph chromosome in CpG ODN treatment of B-ALL not only clarifies the mechanisms of CpG ODN activity against different subtypes but also identifies biomarkers for treatment. The gene discussed is MYC; the disease is acute lymphoblastic leukemia.